Welcome to our dedicated page for Pacira Biosciences SEC filings (Ticker: PCRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pacira BioSciences filings document a life sciences company's financial results, governance actions, credit arrangements and manufacturing-related corporate events. Recent Form 8-K reports furnish quarterly and annual results for the commercial portfolio, including EXPAREL, ZILRETTA and iovera, and disclose the company's common stock listing on the Nasdaq Global Select Market under PCRX.
The filing record also covers board composition and committee appointments, non-employee director compensation, senior secured revolving credit facility terms, and exit or disposal activities associated with EXPAREL manufacturing efficiencies and large-scale production suites. These disclosures frame Pacira's capital structure, liquidity arrangements, operating costs, governance and product-manufacturing infrastructure.
Pacira BioSciences, Inc. director Mark Froimson reported an open-market sale of 500 shares of common stock at $21.81 per share. After this transaction, he directly holds 20,136 shares. This filing reflects a relatively small sale compared with his remaining reported ownership.
PCRX files a Form 144 reporting proposed sale of Common Stock. The filing lists prior acquisitions of Common Stock: 209 shares purchased under an ESPP on 12/31/2021, 2,000 shares acquired on exercise of stock options on 05/23/2022, and 1,052 shares from restricted stock vesting on 06/03/2022. The notice identifies Fidelity Brokerage Services LLC as the broker.
Pacira BioSciences, Inc. is the target of an activist campaign by DOMA Perpetual Capital Management and affiliates, which report beneficial ownership of 2,936,794 common shares, or 7.3% of the company. The group, led by Pedro Escudero, filed Amendment No. 3 to Schedule 13D.
Using 40,489,894 shares outstanding as of February 23, 2026, DOMA and related entities disclose various stakes, including 4.9% held by Doma Perpetual LO Equity Master Fund and 2% reported for The John Templeton Foundation. On March 11, 2026, Doma Master Fund notified Pacira it intends to nominate three directors at the 2026 annual meeting and to solicit proxies.
In a March 12, 2026 press release incorporated in the filing, DOMA called for chief executive officer Frank Lee to be replaced and urged the board to appoint an interim CEO. DOMA also stated its view that Pacira’s stock price has declined over several years while expenses and management compensation have increased, and urged the board to run a formal sale process to maximize value for shareholders.
DOMA Perpetual announced a solicitation to nominate three director candidates to the board of Pacira BioSciences, Inc. and stated it beneficially owns approximately 7.3% of Pacira's common stock. The nominating group urges removal of CEO Frank Lee, requests an interim CEO and a formal sale process, and criticizes multi-year underperformance, management compensation changes to RSUs, and strategic decisions including relocation of headquarters. DOMA names nominees Christopher Dennis, Oliver Benton Curtis III and Eric de Armas, and says it will file a preliminary proxy statement and a WHITE universal proxy card to solicit votes at the 2026 annual meeting.
DOMA Perpetual is soliciting proxies to elect three nominees to the board of Pacira Biosciences and announced its intention to file a preliminary proxy statement and WHITE universal proxy card to be used at the 2026 annual meeting. In a Mar 11, 2026 press release, DOMA says it beneficially owns 7.1% of Pacira common stock and cites sustained underperformance, executive compensation concerns, and strategic disagreements.
DOMA requests the Board name an interim CEO, pursue a formal sale process for the company and replace CEO Frank Lee; it also nominates Christopher Dennis, Oliver Benton Curtis and Eric de Armas to address governance and strategic execution.
DOMA Perpetual is soliciting proxies to elect three nominees to the board of Pacira Biosciences and announced its intention to file a preliminary proxy statement and WHITE universal proxy card to be used at the 2026 annual meeting. In a Mar 11, 2026 press release, DOMA says it beneficially owns 7.1% of Pacira common stock and cites sustained underperformance, executive compensation concerns, and strategic disagreements.
DOMA requests the Board name an interim CEO, pursue a formal sale process for the company and replace CEO Frank Lee; it also nominates Christopher Dennis, Oliver Benton Curtis and Eric de Armas to address governance and strategic execution.
Pacira BioSciences provides a detailed update on its non-opioid pain franchise and growth strategy for the year ended December 31, 2025. EXPAREL remains the core product, with net product sales of $575.1 million, representing 79% of total revenue. ZILRETTA generated net product sales of $116.6 million and iovera° $24.2 million.
The company highlights its “5x30” plan to 2030, targeting double-digit product revenue growth, gross margin improvement and at least five clinical programs and five partnerships. It reports reaching 2.5 million patients in 2025 and adding strategic partnerships for EXPAREL and ZILRETTA.
Pacira expands on its pipeline, led by gene therapy candidate PCRX-201 for knee osteoarthritis, which has Phase 1 data and is in Phase 2 development with RMAT and ATMP designations. It also acquired the remaining stake in GQ Bio Therapeutics and licensed PCRX-2002 from AmacaThera.
The filing describes extensive clinical data supporting EXPAREL, ZILRETTA and iovera°, the IGOR real‑world outcomes registry, manufacturing capacity with Thermo Fisher and internal facilities, and key commercial agreements. It also notes a Paragraph IV settlement that allows limited generic EXPAREL entry starting in early 2030 and a favorable royalty dispute judgment requiring RDF to repay $23.1 million plus $5.2 million interest.
Pacira BioSciences reported modest growth for 2025 and returned to profitability, while laying out guidance for 2026. Total 2025 revenue was $726.4 million, up 4% from 2024, led by EXPAREL net product sales of $575.1 million, a 5% increase.
The company posted 2025 GAAP net income of $7.0 million, or $0.16 per share, compared with a GAAP net loss of $99.6 million in 2024 that included a large goodwill impairment. Non-GAAP net income was $122.3 million, with adjusted EBITDA of $186.5 million, down from $223.9 million.
Pacira repurchased 5.9 million shares in 2025 for $150.0 million, ending the year with 41.1 million shares outstanding and $150.0 million remaining under its authorization. For 2026, it guides to total revenue of $745–$770 million, EXPAREL sales of $600–$620 million and non-GAAP gross margin of 77–79%.
Pacira BioSciences Chief Financial Officer Shawn Cross was granted 49,091 restricted stock units of common stock on February 11, 2026. The award was reported at a price of $0 per share as an acquisition, increasing his directly held common stock to 105,341 shares.
The restricted stock units vest in four equal annual installments beginning on February 15, 2027, if Cross remains in continuous service with Pacira on each vesting date. Each unit represents the right to receive one share of Pacira common stock upon vesting.
Pacira BioSciences Chief Administrative Officer Kristen Williams received an equity award of 54,546 shares of common stock on February 11, 2026. The award is in the form of restricted stock units granted at a price of $0 per share, described as a grant, award, or other acquisition.
These restricted stock units vest in four equal annual installments beginning on February 15, 2027, as long as she remains in continuous service with the company on each vesting date. Each unit represents the right to receive one share of Pacira common stock. Following this grant, Williams beneficially owns 185,849 shares of Pacira common stock directly.